EartheCBD

Understanding the shifts in federal cannabis policy and what they mean for your wellness journey

If you've been following cannabis news lately, you've likely heard that President Trump is expected to sign an executive order that could significantly change how marijuana is classified under federal law. For those of us in the CBD and wellness community, this development brings both promising opportunities and important challenges that deserve a closer look.

The Big Picture: Marijuana Moving to Schedule III

The centerpiece of the expected executive order is a directive to the Justice Department and DEA to complete the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act.

What does this actually mean?

Currently, marijuana sits in Schedule I alongside substances like heroin – a classification that says it has "no accepted medical use" and the highest potential for abuse. This classification has long been at odds with the growing body of research showing cannabis's therapeutic benefits and the millions of Americans who use it for wellness purposes.

Schedule III drugs, by contrast, are recognized as having accepted medical uses with a moderate to low potential for dependence. According to the Drug Enforcement Administration, this category includes substances like ketamine and certain anabolic steroids – a significant shift in federal recognition of cannabis's medical value.

What Changes (And What Doesn't)

It's important to understand what rescheduling would and wouldn't accomplish:

What It Would Do:

• Remove major barriers to cannabis research, making it easier for scientists to study its medical applications
• Allow cannabis businesses to take normal federal tax deductions (currently prohibited under Section 280E of the tax code)
• Enable pharmaceutical companies to more easily develop FDA-approved cannabis medicines
• Signal federal recognition that cannabis has legitimate medical value

What It Wouldn't Do:

• Fully legalize marijuana at the federal level
• Automatically change state laws where cannabis remains illegal
• Immediately impact recreational marijuana sales in states where it's already legal
• Protect consumers or businesses in states where cannabis is prohibited

Think of it as opening doors for research and medicine rather than a full legalization measure.

Banking Access: A Critical Industry Need

One of the most significant practical challenges facing the cannabis industry today is the lack of access to traditional banking services. Because marijuana remains federally illegal, most banks refuse to work with cannabis businesses, forcing many to operate largely in cash.

The expected executive order reportedly encourages Congress to pass the SAFER Banking Act, which would protect financial institutions that serve licensed cannabis businesses. While the executive order itself can't force this change (that requires Congressional action), presidential support could help move this critical legislation forward.

For consumers, improved banking access would mean safer, more professional cannabis retail experiences and potentially lower prices as businesses reduce the costs and risks associated with cash-heavy operations.

Medicare Coverage for CBD: Proceed with Cautious Optimism

Perhaps the most intriguing element for CBD users is the reported provision directing the Centers for Medicare and Medicaid Services (CMS) to explore Medicare coverage for certain CBD-based treatments.

What this could mean: Multiple sources indicate the executive order may push CMS to test or pilot limited Medicare coverage for specific CBD products, particularly those that have been rigorously studied or show promise for conditions common among seniors.

Important caveats:

• Any coverage changes would roll out slowly through regulatory processes
• Initial coverage would likely be very limited in scope
• Don't expect immediate broad coverage at pharmacies
• Clinical evidence and FDA approval processes would still apply
• This is exploratory, not a guarantee of widespread coverage

For now, this represents federal acknowledgment of CBD's potential medical value rather than an immediate practical change for most consumers.

The Hemp-THC Complication: A Challenging Counterpoint

Here's where the picture gets more complicated. While the marijuana rescheduling news has generated excitement, a separate federal law that President Trump has already signed creates significant restrictions on hemp-derived THC products.

The New Hemp Definition: Tucked into a recent federal spending bill is a revised definition of hemp that dramatically limits THC content in final consumer products. According to the Congressional Research Service, this represents a major shift in how hemp products are regulated. Starting November 12, 2026:

• Hemp products can contain no more than approximately 0.4 milligrams of total THC per container
• The restriction applies to all THC isomers, including Delta-8, Delta-9, and Delta-10
• It covers "THC-like" cannabinoids, potentially including products many consumers currently use

Why this matters: This effectively bans most of the intoxicating hemp-derived products currently on the market – the very products many retailers and consumers have turned to as legal alternatives to marijuana. Industry analysts suggest this could eliminate a significant portion of today's hemp-THC market if the rule isn't revised before the 2026 deadline.

Two Paths Diverging: The Regulatory Contradiction

We're witnessing an interesting regulatory paradox: federal marijuana policy is moving toward greater acceptance and medical recognition, while federal hemp-THC policy is becoming significantly more restrictive.

This creates a complex landscape:

• Traditional marijuana products may gain legitimacy, research funding, and potentially easier business operations through rescheduling
• Hemp-derived THC products face an uncertain future as current products may need reformulation or could be removed from the market entirely
• Pure CBD products (without significant THC) should remain largely unaffected by the hemp restrictions but could benefit from increased mainstream acceptance

What This Means for Your Wellness Journey

For consumers who rely on cannabinoid products for wellness:

In the near term:

• CBD products without intoxicating THC levels should continue as available
• Changes from marijuana rescheduling will be gradual, primarily affecting research and business operations
• Any Medicare coverage for CBD would take time to implement
• Hemp-THC products remain legal until November 2026, but manufacturers should prepare for changes

Looking ahead:

• Increased research funding could lead to better understanding of optimal dosing and applications
• More pharmaceutical companies may develop standardized cannabis medicines
• The distinction between "marijuana" and "hemp" products may become more clearly defined
• Consumers may see more scientifically validated cannabis wellness products as research expands

The Bigger Picture: Progress with Complexity

This moment represents significant federal recognition of cannabis's medical value – something the wellness community has understood for years. The expected rescheduling of marijuana is genuinely historic, marking a shift away from decades of prohibition mentality.

At the same time, the hemp-THC restrictions remind us that cannabis policy remains complex and evolving. Regulations don't always move in lockstep, and what benefits one segment of the industry may challenge another.

What You Can Do

As these changes unfold:

1. Stay informed about both federal and state regulations affecting your preferred products
2. Talk to your healthcare provider about cannabinoid use, especially if you have concerns about interactions or conditions. Our team is also available to answer questions about our products
3. Choose reputable vendors who prioritize quality, testing, and regulatory compliance
4. Don't expect immediate changes – regulatory shifts take time to impact day-to-day availability
5. Prepare for the 2026 hemp-THC restrictions if you use products that may be affected

A Time of Transition

We're living through a pivotal moment in cannabis policy. Federal recognition of marijuana's medical potential represents real progress, while new hemp restrictions create genuine challenges. For those of us committed to natural wellness solutions, this means staying adaptable and informed as the regulatory landscape continues to evolve.

The path forward isn't perfectly clear, but one thing is certain: the conversation about cannabis has fundamentally shifted at the federal level. What happens next will depend on implementation details, Congressional action, and continued advocacy for sensible, science-based cannabis policies.

Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. Cannabis and hemp regulations vary by state, and federal law continues to evolve. Always consult with healthcare professionals before starting any new wellness regimen, and ensure compliance with all applicable laws in your jurisdiction. The statements made regarding these products have not been evaluated by the Food and Drug Administration.